Thursday, April 19, 2012

Alder BioPharmaceuticals Lands $38M

Bothell-based Alder BioPharmaceuticals, a developer of technology for developing antibodies used in treating cancer, autoimmune diseases, and other diseases, has raised $38M in a Series D funding round, the company said this morning. The funding was led by Novo Ventures, a new investor in the firm, and also included prior investors Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech. Peter Bisgaard of Novo Ventures joins the company's board with the funding. Alder has now raised over $105M in funding. More information »